Company: CNTB
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001835268-25-000014
Chunk: 4

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-31
Form: 10-K
Item: Item 10
Chunk 4
---
ITEM 10.       DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

Information Concerning the Board of Directors

Certain biographical information regarding each of our directors, including age, position held with us, term of office as director, and business experience, is set forth below:

NameAgePositionYear Elected or AppointedKleanthis G. Xanthopoulos, Ph.D.66Chairman of the Board2020Kan Chen, Ph.D.43Director2020James Z. Huang, MBA59Director2024Jean Liu, J.D.56Director2021Barry D. Quart, Pharm.D.68Chief Executive Officer and Director2024Karen J. Wilson, CPA61Director2020

There are no arrangements or understandings between any of our directors and any other persons pursuant to which any director was selected as a director.

Kleanthis G. Xanthopoulos, Ph.D. (Chairman), has served on our Board since 2020 and was appointed as Chairman in 2024. Dr. Xanthopoulos has over 28 years of experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor, and member of various boards of directors. Dr. Xanthopoulos has served as Chairman & Chief Executive Officer of Shoreline Biosciences, Inc. and Chairman of Stork Capital Life Sciences, which focuses on building and investing in innovative biotechnology companies, since 2020. He previously served as Chief Executive Officer of IRRAS AB and President and Chief Executive Officer of Regulus Therapeutics, Inc. He also previously served on the board of directors of Zosano Pharma Corporation. Dr. Xanthopoulos is an Onassis Scholar and was at NIH Human Genome Research Institute. Dr. Xanthopoulos received a B.S. in Biology from Aristotle University of Thessaloniki, Greece, an M.Sc. in Microbiology, and a Ph.D. in Molecular Biology from the University of Stockholm, Sweden.

Our Nominating and Corporate Governance Committee and our Board believe that Dr. Xanthopoulos is qualified to serve on our Board due to his extensive expertise and experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor, and as a director of other public and private biotechnology and pharmaceutical companies. 

Kan Chen, Ph.D., has served on our Board since 2020. Dr. Chen is a Partner of Qiming Venture Partners, focusing on healthcare